Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug
Khokon Miah Akanda, Senior Brand Executive at Apex Pharma Limited, shared on LinkedIn:
“FDA approves a first-in-class hypertension drug!
The US FDA has recently approved Baxfendy (baxdrostat) by AstraZeneca, the first-ever aldosterone synthase inhibitor for hypertension treatment.
What makes this approval significant is its completely new mechanism of action. Instead of only managing symptoms, the drug directly targets aldosterone production, a hormone linked to persistently high blood pressure and cardiovascular risk.
In Phase III trials, the drug demonstrated clinically meaningful reductions in systolic blood pressure in patients whose hypertension remained uncontrolled despite multiple medications.
This marks one of the most important cardiovascular drug innovations in recent years and highlights how pharma continues to evolve toward more targeted and mechanism-based therapies.
Exciting to see innovation reshaping chronic disease management.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 05:35Does LDL Cholesterol Influence VTE Risk? – Ordo Fraterna Fibonacci
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients
-
Aug 31, 2026, 04:28Reza Hafidz Irawan։ Automated Antibody Titration With Erytra Eflexis
-
Aug 31, 2026, 04:17Safa Chenganath: Stenosis vs Thrombosis – Hemodialysis Vascular Access
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session